HYPERTONIC SALINE IN ACUTE VIRAL BRONCHIOLITIS: A RANDOMIZED CLINICAL TRIAL

• Status: Withdrawn
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether nebulized hypertonic saline solution reduces the admission rate 48 hours after initial treatment in the emergency department, when compared to normal saline solution (placebo). We hypothesise that patients with bronchiolitis who receive nebulized hypertonic saline solution will have less respiratory distress, less duration of symptoms and therefore less risk of being hospitalized than those receiving normal saline solution.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Laval University
• Collaborators: Canadian Institutes of Health Research (CIHR); Centre de Recheche du Centre Hospitalier Université Laval
• Treatments: Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• clinical diagnosis of viral bronchiolitis

• Age 6 weeks to 12 months

• Clinical Score IRAS >3 and <8

Exclusion Criteria:

• prematurity <30 weeks

• younger than 6 weeks of age

• chronic lung disease

• immunosuppression.

• History of wheezing or asthma.

• Clinical Score IRAS >9

• parents refuse study